Updates on clinical trials evaluating the regenerative potential of allogenic mesenchymal stem cells in COVID-19

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected nearly 118 million people and caused ~2.6 million deaths worldwide by early 2021, during the coronavirus disease 2019 (COVID-19) pandemic. Although the majority of infected patients show mild-to-moderate symptoms, a s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dhavan Sharma, Feng Zhao
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R
Acceso en línea:	https://doaj.org/article/bb53f96681ee48e2be6b92f9baa0d833
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bb53f96681ee48e2be6b92f9baa0d833
record_format	dspace
spelling	oai:doaj.org-article:bb53f96681ee48e2be6b92f9baa0d8332021-12-02T18:18:47ZUpdates on clinical trials evaluating the regenerative potential of allogenic mesenchymal stem cells in COVID-1910.1038/s41536-021-00147-x2057-3995https://doaj.org/article/bb53f96681ee48e2be6b92f9baa0d8332021-06-01T00:00:00Zhttps://doi.org/10.1038/s41536-021-00147-xhttps://doaj.org/toc/2057-3995Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected nearly 118 million people and caused ~2.6 million deaths worldwide by early 2021, during the coronavirus disease 2019 (COVID-19) pandemic. Although the majority of infected patients show mild-to-moderate symptoms, a small fraction of patients develops severe symptoms. Uncontrolled cytokine production and the lack of substantive adaptive immune response result in hypoxia, acute respiratory distress syndrome (ARDS), or multiple organ failure in severe COVID-19 patients. Since the current standard of care treatment is insufficient to alleviate severe COVID-19 symptoms, many clinics have been prompted to perform clinical trials involving the infusion of mesenchymal stem cells (MSCs) due to their immunomodulatory and therapeutic properties. Several phases I/II clinical trials involving the infusion of allogenic MSCs have been performed last year. The focus of this review is to critically evaluate the safety and efficacy outcomes of the most recent, placebo-controlled phase I/II clinical studies that enrolled a larger number of patients, in order to provide a statistically relevant and comprehensive understanding of MSC’s therapeutic potential in severe COVID-19 patients. Clinical outcomes obtained from these studies clearly indicate that: (i) allogenic MSC infusion in COVID-19 patients with ARDS is safe and effective enough to decreases a set of inflammatory cytokines that may drive COVID-19 associated cytokine storm, and (ii) MSC infusion efficiently improves COVID-19 patient survival and reduces recovery time. These findings strongly support further investigation into MSC-infusion in larger clinical trials for COVID-19 patients with ARDS, who currently have a nearly 50% of mortality rate.Dhavan SharmaFeng ZhaoNature PortfolioarticleMedicineRENnpj Regenerative Medicine, Vol 6, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R
spellingShingle	Medicine R Dhavan Sharma Feng Zhao Updates on clinical trials evaluating the regenerative potential of allogenic mesenchymal stem cells in COVID-19
description	Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected nearly 118 million people and caused ~2.6 million deaths worldwide by early 2021, during the coronavirus disease 2019 (COVID-19) pandemic. Although the majority of infected patients show mild-to-moderate symptoms, a small fraction of patients develops severe symptoms. Uncontrolled cytokine production and the lack of substantive adaptive immune response result in hypoxia, acute respiratory distress syndrome (ARDS), or multiple organ failure in severe COVID-19 patients. Since the current standard of care treatment is insufficient to alleviate severe COVID-19 symptoms, many clinics have been prompted to perform clinical trials involving the infusion of mesenchymal stem cells (MSCs) due to their immunomodulatory and therapeutic properties. Several phases I/II clinical trials involving the infusion of allogenic MSCs have been performed last year. The focus of this review is to critically evaluate the safety and efficacy outcomes of the most recent, placebo-controlled phase I/II clinical studies that enrolled a larger number of patients, in order to provide a statistically relevant and comprehensive understanding of MSC’s therapeutic potential in severe COVID-19 patients. Clinical outcomes obtained from these studies clearly indicate that: (i) allogenic MSC infusion in COVID-19 patients with ARDS is safe and effective enough to decreases a set of inflammatory cytokines that may drive COVID-19 associated cytokine storm, and (ii) MSC infusion efficiently improves COVID-19 patient survival and reduces recovery time. These findings strongly support further investigation into MSC-infusion in larger clinical trials for COVID-19 patients with ARDS, who currently have a nearly 50% of mortality rate.
format	article
author	Dhavan Sharma Feng Zhao
author_facet	Dhavan Sharma Feng Zhao
author_sort	Dhavan Sharma
title	Updates on clinical trials evaluating the regenerative potential of allogenic mesenchymal stem cells in COVID-19
title_short	Updates on clinical trials evaluating the regenerative potential of allogenic mesenchymal stem cells in COVID-19
title_full	Updates on clinical trials evaluating the regenerative potential of allogenic mesenchymal stem cells in COVID-19
title_fullStr	Updates on clinical trials evaluating the regenerative potential of allogenic mesenchymal stem cells in COVID-19
title_full_unstemmed	Updates on clinical trials evaluating the regenerative potential of allogenic mesenchymal stem cells in COVID-19
title_sort	updates on clinical trials evaluating the regenerative potential of allogenic mesenchymal stem cells in covid-19
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/bb53f96681ee48e2be6b92f9baa0d833
work_keys_str_mv	AT dhavansharma updatesonclinicaltrialsevaluatingtheregenerativepotentialofallogenicmesenchymalstemcellsincovid19 AT fengzhao updatesonclinicaltrialsevaluatingtheregenerativepotentialofallogenicmesenchymalstemcellsincovid19
_version_	1718378240144310272

Updates on clinical trials evaluating the regenerative potential of allogenic mesenchymal stem cells in COVID-19

Ejemplares similares